SecBot SecBot

IRMD

IRADIMED CORP
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001325618 Healthcare & Medical Devices
$84.63 −1.19 (−1.39%)
Oct 26 4:00 PM ET · prev $85.82
Market cap
$1.1B
Small cap
Consensus
Buy
78% Buy or better · 9 analysts
Median target
$118.00
+39% · range $116.00–120.00
Next earnings
Oct 29
in 2 days · EPS est. $0.55
1 year
+8.9%
from $77.73 · Oct 27
30 days
−2.3%
from $86.66
52-week range
$76.42–105.15
−20% from high · low Oct 30
Avg volume 20D
112.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$5.3M
0 buyers · 3 sellers · since Apr 13
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 mixed oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Oct 29, 2026
Strongest MIXED IRADIMED reported Q2 2026 revenue of $20.5M (+0.5% YoY) but GAAP EPS fell 9% to $0.41 and net income dropped…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $5.3M.

  • InstitutionsBULLISH

    Q2 2026: 19 added (0 new), 10 trimmed or exited.

  • AnalystsBULLISH

    7 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate $0.540 → $0.550 over 90 days. 1 up, 0 down in 30 days.

  • TrendRANGE

    2% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdADD157,199$15.0M
ROYAL BANK OF CANADADOUBLED148,179$14.2M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED143,969$13.8M
FIRST TRUST ADVISORS LPDOUBLED84,318$8.1M
Nuveen, LLCTRIM61,650$5.9M
SEI INVESTMENTS COTRIM47,686$4.6M
TUDOR INVESTMENT CORP ET ALTRIM45,626$4.4M
WELLS FARGO & COMPANY/MNADD41,317$3.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 78% rate it Buy or better
Strong Buy2Buy5Hold2Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +39%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 22, 2026Needham
INITIATE
INITIATEHold

Insider ledger

Form 4
$0
bought · 0 insiders
$5.3M
sold · 3 insiders
DateInsiderTypeValue
Sep 23, 2026
KIANI JOE E
Director
EXERCISE698 sh
Sep 3, 2026
ALLEN MONTY K
Director
SELL$87.7K
Sep 3, 2026
ALLEN MONTY K
Director
SELL$35.0K
Jun 20, 2026
GLENN JOHN
CFO
EXERCISE5,796 sh
Jun 20, 2026
GLENN JOHN
CFO
TAX W/H$213.8K
Jun 4, 2026
Scharen-Guivel Hilda Frederique
Director
SELL$167.8K
Jun 4, 2026
Scharen-Guivel Hilda Frederique
Director
SELL$117.2K
Jun 1, 2026
Susi Roger E.
CEO, President, Chairman
SELL$35.5K

Earnings setup

Estimates
Oct 29
reports in 2 days
$0.55
EPS estimate, this quarter
+2%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.55$0.54–$0.56+0.9%$23.4M
Next Q$0.63$0.61–$0.66+2.4%$26.2M
Current FY$2.11$2.09–$2.16+1.1%$92.1M
Next FY$2.45$2.40–$2.54+1.8%$104.1M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Insider
KIANI JOE E acquired via exercise 698 shares
Director
Sep 3, 2026 Insider
ALLEN MONTY K sold 1,014 shares
Director @ $86.44 ($87.7K)
Sep 3, 2026 Insider
ALLEN MONTY K sold 405 shares
Director @ $86.35 ($35.0K)
Jul 31, 2026 SEC
IRADIMED reported Q2 2026 revenue of $20.5M (+0.5% YoY) but GAAP EPS fell 9% to $0.41 and net income dropped 10% to…
8-K — Impact 5/10
Jul 31, 2026 SEC
iRadimed reported Q2 2026 revenue of $20.5M (slightly above $20.4M consensus) and non-GAAP EPS of $0.46 (beat $0.44…
PRESS-RELEASE — Impact 5/10
Jul 31, 2026 Earnings
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share
Jul 24, 2026 SEC
iRadimed Corporation announced it will host a conference call on July 31, 2026 to discuss its Q2 2026 results.
PRESS-RELEASE — Impact 1/10
Jun 30, 2026 Inst.
Qube Research & Technologies — ADD
157,199 shares ($15.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 29, 2026
Earnings date
IRMD Q3 2026 Earnings Scheduled — 2026-10-29
Recent
Jul 31, 2026
Earnings
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share
Jul 31, 2026
Earnings date
IRMD Q2 2026 Earnings Scheduled — 2026-07-31
Jul 30, 2026
Earnings date
IRMD Q2 2026 Earnings Scheduled — 2026-07-30
Jul 24, 2026
Earnings
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second…
May 20, 2026
Earnings
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical…

SecBot reports

7 filings · 1 bullish · 0 bearish · 2 mixed · 4 neutral
All IRMD filing & press-release reports (7)